| Literature DB >> 35476785 |
Talia M Quandelacy1,2, Laura E Adams1, Jorge Munoz1, Gilberto A Santiago1, Sarah Kada1, Michael A Johansson1, Luisa I Alvarado3, Vanessa Rivera-Amill3, Gabriela Paz-Bailey1.
Abstract
INTRODUCTION: Impacts of COVID-19 mitigation measures on seasonal respiratory viruses is unknown in sub-tropical climates.Entities:
Mesh:
Year: 2022 PMID: 35476785 PMCID: PMC9045654 DOI: 10.1371/journal.pone.0266095
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Fig 1Number tested and test positivity for SARS-CoV-2, influenza A & B, respiratory syncytial virus (RSV), respiratory adenovirus (AdV), and other respiratory viruses (human metapneumovirus and human parainfluenza virus types 1 & 3) from the 2012–2019 respiratory seasons, southern Puerto Rico, SEDSS.
Line types indicate the different respiratory seasons. The trend the average weekly percent test-positive from surveillance week 40 to 39 across the 2012–13 to 2018–19 seasons. The vertical dashed line corresponds to March 15, 2020 (week 12), when island-wide COVID-19 mitigation measures were implemented.
Number tested and test-positivity of influenza and other viral respiratory pathogens in the 2019–20 season compared to the average across the 2012–18 seasons, overall and before and after implementation of COVID-19 mitigation measures in southern Puerto Rico, SEDSS.
| A) Entire season (Weeks 40 to 39) | B) Period before COVID-19 mitigation measures (Weeks 40 to 11) | C) Period after COVID-19 mitigation measures (Weeks 12 to 39) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 2019–20 | 2012–18 average season | 2019–20 | 2012–18 average season* | 2019–20 | 2012–18 average season* | ||||
|
| 2,439 | 3,604 | P<0.001 | 1,674 | 1,624 | P = 0.69 | 765 | 1,980 | P<0.001 |
|
| 154 (6%) | 387 (11%) | P<0.001 | 154 (9%) | 250 (15%) | P<0.01 | 0 (0%) | 137 (7%) | P<0.001 |
|
| 118 (5%) | 165 (5%) | P = 0.05 | 117 (7%) | 98 (6%) | P = 0.91 | 1 (<1%) | 67 (2%) | P<0.001 |
|
| 134 (5%) | 133 (4%) | P<0.001 | 134 (8%) | 95 (6%) | P = 0.13 | 0 (0%) | 38 (2%) | P<0.001 |
|
| 95 (4%) | 159 (4%) | P<0.001 | 90 (5%) | 60 (4%) | P = 0.62 | 5 (1%) | 99 (5%) | P<0.05 |
|
| 80 (3%) | 229 (6%) | P<0.001 | 80 (5%) | 112 (7%) | P = 0.02 | 0 (0%) | 117 (6%) | P<0.001 |
Other respiratory viruses are laboratory-confirmed cases of human metapneumovirus and human parainfluenza virus types 1 & 3.
*The average trend is the average weekly percent test-positive from surveillance week 40 to 39 across the 2012–13 to 2018–19 seasons.
†Two-sided p-value for Wilcoxon signed rank test assessed the pairwise difference between weekly outcomes (weekly number of tests and weekly test-positivity) across the entire 2019–2020 season compared and the average across the 2012–18 seasons (weeks 40 to 39).
‡One-sided p-value for Wilcoxon signed rank test assessing if weekly outcomes were lower in the 2019–20 season (comparing weeks 40 to 11, i.e., before COVID-19 mitigation measures) compared to the average across the 2012–18 seasons.
§One-sided p-value for Wilcoxon signed rank test assessing if weekly outcomes were lower in the 2019–20 season (weeks 12 to 39, i.e., after COVID-19 mitigation measures) compared to the average across the 2012–18 seasons. Abbreviations: RSV, respiratory syncytial virus; AdV, respiratory Adenovirus.